News

Show
news from

Achilles Therapeutics Provides Business Update and Outlook for 2022

Achilles Therapeutics Added to the NASDAQ Biotechnology Index

Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens

Achilles Therapeutics Presents Data at the SITC Annual Meeting

Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights

Achilles Therapeutics Presents Data at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress Demonstrating its Proprietary Manufacturing Process Can Generate Potent, Personalized Anti-Cancer Cell Therapy Candidates in Multiple Tumor Types

Load more

Search